{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:01:11Z","timestamp":1787508071421,"version":"build-2736575974"},"reference-count":92,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cpcardiol.2023.101740","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T19:56:57Z","timestamp":1681243017000},"page":"101740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel Treatments of Hypertrophic Cardiomyopathy in GDMT for Heart Failure: A State-of-art Review"],"prefix":"10.1016","volume":"48","author":[{"given":"Mehrdad","family":"RabieeRad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-874X","authenticated-orcid":false,"given":"Ghazal","family":"GhasempourDabaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Amani-beni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2023.101740_bib0001","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0002","unstructured":"Hajouli S, Ludhwani D. Heart Failure And Ejection Fraction. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC: Tampa, Florida, United States, 2023."},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0003","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0004","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/ehf2.13859","article-title":"Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care","volume":"9","author":"Tomasoni","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0005","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0006","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/ejhf.1557","article-title":"Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials","volume":"21","author":"Ahmad","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0007","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2217\/fca-2021-0044","article-title":"A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy","volume":"17","author":"Burstein Waldman","year":"2021","journal-title":"Future Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0008","first-page":"1","article-title":"Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis","author":"Dini","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249599","article-title":"Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases","volume":"21","author":"Alsulami","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0010","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","article-title":"The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial","volume":"378","author":"Cleland","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0012","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0022-3565(24)39031-7","article-title":"Different effect of the Ca(2+) sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium","volume":"295","author":"Brixius","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0013","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0022-3565(24)36366-9","article-title":"Ca++ sensitizers impair cardiac relaxation in failing human myocardium","volume":"280","author":"Hajjar","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0014","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","article-title":"Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure","volume":"36","author":"Nieminen","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101740_bib0015","first-page":"S18","article-title":"Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure","volume":"14","author":"Pouleur","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01745236","article-title":"Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure","volume":"9","author":"Sasayama","year":"1994","journal-title":"Heart Vessels"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0017","first-page":"483","article-title":"Dose-dependent electrophysiological effects of the myosin activator omecamtiv mecarbil in canine ventricular cardiomyocytes","volume":"67","author":"Szentandrassy","year":"2016","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0018","doi-asserted-by":"crossref","first-page":"e01603","DOI":"10.7554\/eLife.01603","article-title":"Small molecule-mediated refolding and activation of myosin motor function","volume":"3","author":"Radke","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0019","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","article-title":"Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan","volume":"159","author":"Papp","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0020","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.RES.63.5.911","article-title":"Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone","volume":"63","author":"Fujino","year":"1988","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0021","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0022-3565(25)20195-1","article-title":"Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats","volume":"252","author":"Fujimoto","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0022","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41467-017-00176-5","article-title":"Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil","volume":"8","author":"Planelles-Herrero","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0023","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","article-title":"Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study","volume":"67","author":"Teerlink","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0024","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2022.11016","article-title":"Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial","volume":"328","author":"Lewis","year":"2022","journal-title":"Jama"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0025","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.tcm.2016.03.011","article-title":"Digoxin: the good and the bad","volume":"26","author":"Ziff","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0026","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ehf2.12264","article-title":"Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure","volume":"5","author":"Shirakabe","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0027","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40262-021-01014-0","article-title":"Effect of varying degrees of renal impairment on the pharmacokinetics of omecamtiv mecarbil","volume":"60","author":"Trivedi","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0028","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jacc.2021.04.065","article-title":"Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF","volume":"78","author":"Teerlink","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0029","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/eurheartj\/ehac144","article-title":"Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial","volume":"43","author":"Solomon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0030","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1093\/eurheartj\/ehac293","article-title":"Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial","volume":"43","author":"Metra","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0031","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jacc.2003.11.037","article-title":"Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"43","author":"Rouleau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0032","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchf.2014.07.009","article-title":"Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina","volume":"3","author":"Greenberg","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0033","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpdd.1028","article-title":"Pharmacokinetic drug-drug interaction study of omecamtiv mecarbil with amiodarone and digoxin in healthy subjects","volume":"11","author":"Trivedi","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0034","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/bdd.2293","article-title":"Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator","volume":"42","author":"Trivedi","year":"2021","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0035","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/01.CIR.101.9.1040","article-title":"Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033","volume":"101","author":"Senzaki","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0036","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00005344-200101000-00003","article-title":"Positive inotropic effects of calcium sensitizers on normal and failing cardiac myocytes","volume":"37","author":"Tsutsui","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0037","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bjp.0704292","article-title":"Beneficial effects of the Ca2+ sensitizer EMD 57033 in exercising pigs with infarction-induced chronic left ventricular dysfunction","volume":"134","author":"Duncker","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0038","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/sj.bjp.0701491","article-title":"Cardiovascular effects of the novel Ca2+-sensitiser EMD 57033 in pigs at rest and during treadmill exercise","volume":"122","author":"Stubenitsky","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0039","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0008-6363(97)00215-0","article-title":"Shortening versus isometric contractions in isolated human failing and non-failing left ventricular myocardium: dependency of external work and force on muscle length, heart rate and inotropic stimulation","volume":"37","author":"Holubarsch","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0040","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1054\/jcaf.2000.19237","article-title":"Differential alteration of cardiotonic effects of EMD 57033 and beta-adrenoceptor agonists in volume-overload rabbit ventricular myocytes","volume":"6","author":"Sugawara","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0041","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/01.RES.87.3.235","article-title":"Alterations in the determinants of diastolic suction during pacing tachycardia","volume":"87","author":"Bell","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0042","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/euhj.1997.0806","article-title":"Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting","volume":"19","author":"Lilleberg","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0043","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1067\/mcp.2000.110972","article-title":"Myocardial efficiency during levosimendan infusion in congestive heart failure","volume":"68","author":"Ukkonen","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0044","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","article-title":"Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure","volume":"9","author":"Lilleberg","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0045","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0046","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","article-title":"Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study investigators","volume":"102","author":"Slawsky","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0047","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"Jama"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0048","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0049","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.118","article-title":"Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial","volume":"16","author":"Altenberger","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejheart.2006.06.001","article-title":"Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure","volume":"9","author":"Berger","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0051","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0052","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/FJC.0b013e31826b86aa","article-title":"Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival","volume":"60","author":"Malfatto","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0053","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ehf2.12272","article-title":"Haemodynamic effects of levosimendan in advanced but stable chronic heart failure","volume":"5","author":"Najjar","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0054","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0300060516655244","article-title":"Intermittent levosimendan infusions in advanced heart failure: a real world experience","volume":"45","author":"Ortis","year":"2017","journal-title":"J Int Med Res"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0055","first-page":"1768","article-title":"Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure","volume":"92","author":"Parissis","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0056","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.hlc.2007.10.014","article-title":"Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience","volume":"17","author":"Parle","year":"2008","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0057","doi-asserted-by":"crossref","first-page":"276","DOI":"10.12659\/MSM.889767","article-title":"Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure","volume":"20","author":"Tasal","year":"2014","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0058","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1586\/14779072.2015.1071664","article-title":"The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management","volume":"13","author":"Ibrahim","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0059","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2016.07.202","article-title":"Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper","volume":"222","author":"Farmakis","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0060","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.jacc.2009.01.075","article-title":"Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality?","volume":"53","author":"Gheorghiade","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0061","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jacc.2018.03.454","article-title":"Similar BNP and mortality association in patients with and without heart failure: any increase matters","volume":"71","author":"Vodovar","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0062","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00134-010-2073-4","article-title":"Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods","volume":"37","author":"Mebazaa","year":"2011","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0063","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"Jama"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0064","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/CCM.0b013e318232962a","article-title":"Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies","volume":"40","author":"Landoni","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","article-title":"Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the flolan international randomized survival trial (FIRST)","volume":"138","author":"O'Connor","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0066","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (ADHERE)","volume":"46","author":"Abraham","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0067","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00134-011-2435-6","article-title":"Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials","volume":"38","author":"Tacon","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0068","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/ACO.0b013e3282f357a5","article-title":"Levosimendan: current status and future prospects","volume":"21","author":"Archan","year":"2008","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0069","doi-asserted-by":"crossref","first-page":"532","DOI":"10.5603\/CJ.2011.0009","article-title":"Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure","volume":"18","author":"Lunghetti","year":"2011","journal-title":"Cardiol J"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0070","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cardfail.2007.04.004","article-title":"A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure","volume":"13","author":"Mavrogeni","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0071","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.amjcard.2004.11.033","article-title":"Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone","volume":"95","author":"Nanas","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0072","first-page":"269","article-title":"Assessment of quality of life using three activity questionnaires in heart failure patients after monthly, intermittent administration of levosimendan during a six-month period","volume":"50","author":"Papadopoulou","year":"2009","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0073","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/01.RES.68.3.689","article-title":"Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium","volume":"68","author":"B\u00f6hm","year":"1991","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0074","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0022-3565(25)13394-6","article-title":"Differential effects of d- and l-pimobendan on cardiac myofilament calcium sensitivity","volume":"247","author":"Fujino","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.101740_bib0075","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00005344-199506261-00003","article-title":"Mechanisms of action of calcium-sensitizing drugs","volume":"26","author":"Haikala","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0076","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/BF00167264","article-title":"Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart","volume":"339","author":"Brunkhorst","year":"1989","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0077","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/00005344-199424050-00007","article-title":"Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure","volume":"24","author":"Remme","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101740_bib0078","first-page":"S31","article-title":"Effects of pimobendan on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy: comparison with nitroprusside","volume":"14","author":"Hasenfuss","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101740_bib0079","first-page":"S23","article-title":"Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure","volume":"14","author":"Baumann","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0080","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/eurheartj\/12.8.889","article-title":"Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril\u2014a double-blind randomized study","volume":"12","author":"Erlemeier","year":"1991","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101740_bib0081","first-page":"S49","article-title":"Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril","volume":"14","author":"Hauf","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101740_bib0082","first-page":"S36","article-title":"Acute effects of intravenous UD-CG 115 BS (pimobendan) on the cardiovascular system and left ventricular pump function","volume":"14","author":"Permanetter","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.101740_bib0083","first-page":"S41","article-title":"Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction","volume":"14","author":"Remme","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0084","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/hrt.76.3.223","article-title":"Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial","volume":"76","author":"Lubsen","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0086","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0002-8703(92)90752-H","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure","volume":"123","author":"Katz","year":"1992","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0087","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/01.CIR.85.3.942","article-title":"Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The pimobendan multicenter research group","volume":"85","author":"Kubo","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0088","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1253\/circj.66.149","article-title":"Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study)","volume":"66","year":"2002","journal-title":"Circ J"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0089","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1006\/jmcc.1996.0241","article-title":"Differential modulation of cytokine production by drugs: implications for therapy in heart failure","volume":"28","author":"Matsumori","year":"1996","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1020652506588","article-title":"Inotropic agents and immune modulation","volume":"16","author":"Sasayama","year":"2002","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0091","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/01.CIR.98.2.100","article-title":"Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure","volume":"98","author":"Wong","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101740_bib0092","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43044-023-00328-7","article-title":"Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials","volume":"75","author":"Rabiee Rad","year":"2023","journal-title":"Egypt Heart J"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623001573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623001573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:18:42Z","timestamp":1758939522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623001573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":92,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0146280623001573"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101740","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Treatments of Hypertrophic Cardiomyopathy in GDMT for Heart Failure: A State-of-art Review","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101740"}}